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Since several years, adult/perinatal mesenchymal and 
neural crest stem cells have been widely used to help 
experimental animal to recover from spinal cord 
injury. More interestingly, recent clinical trials 
confirmed the beneficial effect of those stem cells, 
which improve functional score of patients suffering 
from such lesions. However, a complete 
understanding of the mechanisms of stem cell-
induced recovery is seriously lacking. Indeed, spinal 
cord injuries gathered a wide range of biochemical 
and physiopathological events (such as inflammation, 
oxidative stress, axonal damage, demyelination, etc) 
and the genuine healing process after cell 
transplantation is not sufficiently defined. This 
review aims to sum up recent data about cell therapy 
in spinal cord lesions using mesenchymal or recently 
identified neural crest stem cells, by describing 
precisely which physiopathological parameter is 
affected and the exact processes underlying the 
observed changes. Overall, although significant 
advances are acknowledged, it seems that further 
deep mechanistic investigation is needed for the 






1. Mesenchymal and neural crest stem cells - 
Definition and rationale for SCI treatment 
Mesenchymal stem cells (MSCs) in the adult 
bone marrow stroma were first identified in the 
last 70’s by Friedenstein et al. [1, 2] as colony-
forming unit fibroblast-like cells. Those 
mesoderm-derived cells were subsequently 
described to be self-renewable and highly 
multipotent, giving rise to different cells of 
mesodermal origin such as adipocytes, 
chondrocytes, and osteocytes[3, 4]. In the 
following years, MSC were isolated from other 
adult tissues (ex: fat tissue [5], muscle [6], 
synovium [7], peripheral blood and circulatory 
system [8],…), where they contribute and 
regulate organ physiology and homeostasis. In 
addition, it was shown that MSCs were also 
present in perinatal tissues like umbilical cord 
blood [9] or Wharton’s jelly [10], amniotic 
fluid [11] and placenta [12] (Table 1). 
 
Bone marrow stromal cells (BMSCs) were 
especially considered for cell therapy in 
neurological lesions regarding their capacity to 
give rise to neural-like cells [13-15]. However, 
in vivo neural differentiation is currently matter 
of debate and it seems that adult BMSCs would 
rather help lesion recovery through many other 





mechanisms than in-host differentiation [16, 
17]. Indeed, beside the immunomodulatory 
effects and the secretion of several 
neurotrophic factors, those cells have an anti-
inflammatory effect, making them attractive 
candidates as the most efficient treatment for 
SCI, so far, is a high dose of 
methylprednisolone (anti-inflammatory drug) 
[18]. Moreover, a recent clinical trial showed 
that BMSCs transplantation inside the 
cerebrospinal fluid of spinal cord-injured 
patients modestly enhanced motor and 
sensitive functions. As this work provided first 
clues about BMSCs relevancy for SCI 
treatment, the underlying ways of recovery 
observed in these cases were not explained 
[19]. 
 
More recently, neural crest stem cells (NCSCs) 
were identified inside the adult bone marrow 
[20, 21]. Those cells initially derive from 
neural crest, which arises at the borders of the 
neural tube during embryonic development of 
the nervous system. NCSCs then migrate 
towards different organs, where they 
differentiate to give rise to peripheral neurons 
and glia, melanocytes, chondrocytes, smooth 
muscle cells, etc. Adult NCSCs were identified 
in several post-natal organs [22], intermingled 
with MSCs inside the bone marrow [15, 20, 23, 
24], skin [25-27], gut [28], teeth [29, 30], heart 
[31], palatum [32], cornea [33], and olfactory 
tissue [34-36] (Table 1). 
 
Inside the bone marrow stroma, both MSCs 
and NCSCs accumulate at the bone epiphysis, 
and they are consequently often studied 
together and referred as bone marrow stromal 
cells or BMSCs. This fact makes BMSCs even 
more attractive for SCI treatment as beside the 
inflammatory modulation effects provided by 
MSCs, NCSCs may be the perfect candidate 
for cell replacement therapy. Indeed, due to 
their neural origin, neural crest cells are closely 
related to neural tube stem cells, which makes 
them in close ontological relationship with the 
spinal cord [37]. Furthermore, NCSC express 
the neural crest stem cell molecular signature 
genes that were initially used to create induced 
pluripotent stem cells (iPS) [38]. This last fact 
makes adult NCSCs more attractive than iPS or 
ES cells according to the guidelines for the 
clinical translation of stem cells, published by 
the International Society For Stem Cell 
Research - ISSCR : « …maximum effort 
should be made to minimize the risks for all 
possible adverse events associated with stem 
cell based therapy. » Therefore, adult bone 
marrow NCSCs are more suitable as they are 
not genetically modified like iPS and are less 
immunogenic (similarly to BMSCs) than ES 
cells. 
 
According to the last update reported by Lee et 
al. [39], the global incidence of traumatic 
spinal cord injuries (SCI) was estimated in 
2007 at 23 cases per million worldwide. 
Reported SCI cases mainly concern young 
adults, among them 80% of men, who are for 
the most part victim from motor vehicle 
accidents and falls [40]. The cervical spine and 
lumbar spine are the most commonly affected 
regions, and regarding the level of injury, those 
patients could suffer from para- or tetraplegia. 
Besides locomotor impairments, neuropathic 
pain, reflexive and sensitive troubles also 
occur, accompanied by highly disabling social 
and financial issues. In the last decade, 
although numerous reports have shown 
significant improvements in medical 
management and clinical recuperation after 
SCI, there is still no effective treatment that 
completely allows functional recovery. 
 
The development of such effective treatments 
should first be based on the full understanding 
of SCI physiopathological events, which are 
gathered in three major phases. Briefly, the 
first events after traumatic SCI and spinal 
shock, named the acute phase, encompass 
neuronal necrosis, and axonal disruption, blood 
supply default, edema and accumulation of 
electrolytes, calcium but also potassium and 
excitotoxic neurotransmitters. The intermediate 
phase starts a few minutes after the lesion, and 
lasts for several weeks. It is characterized by 
further ischemia, oxidative stress taking place 
by free-radical production and lipid 
peroxidation, as well as by the recruitment of 
neutrophils and lymphocytes which secrete 
cytokines and promote the development of an 
inflammatory environment. The chronic phase 
arises after few months, covering continuous 
alteration of ionic balance, apoptosis of 





oligodendrocytes and demyelination, formation 
of cavities, and astroglial scar formation 
(reviewed by Oyinbo et al., in 2011 [41] and 
by Ronaghi et al., in 2010 [42]) (Figure 1). 
 
Altogether, those unfavorable events hamper 
axonal regrowth and functional recovery. 
Therefore, in this review, we will detail 
updated evidences (coming from either in vitro 
or in vivo pre-clinical experiments performed 
in the seven last years) about the different 
abilities of adult MSCs and NCSCs to manage 
neural tissue-associated oxidative stress, 
inflammation or apoptosis, neurodegeneration 
and demyelination, which could be highly 
relevant in spinal cord injury cases and provide 
new clues about the precise mechanisms that 
could trigger recovery. All the data gathered in 
this review are classified in an order which 
follows the temporal progression of spinal cord 
injuries as suggested by the most relevant 
studies in that field. Still we keep in mind that 
transplanted MSCs/NCSCs can act on different 
events concomitantly, soon after the injury or 
later. 
 
2. Various properties of mesenchymal and 
neural crest stem cells and spinal cord 
injury treatment 
2.1. Acute phase events: Axonal 
degeneration, ion balance disruption and 
excitotoxicity. 
2.1.1. Neurotrophic support by 
MSCs/NCSCs and protection against 
glutamate toxicity. 
Traumatic damages to the spinal cord induce 
axonal interruptions that are more or less 
complete according to the degree of injury. 
Regrowth of disrupted nervous fibers are 
highly hampered first by the hostile 
environment and later on, by the astroglial 
scar, which significantly inhibits nerve 
regeneration and prevents axons to go through. 
Synergistic strategies could be considered in 
order to enhance axonal regrowth, combining 
neurotrophic factor supply to degenerated 
axons; and afterwards, degradation of 
extracellular matrix/glial scar and 
reconstitution of their myelin sheaths (see 
below). 
 
Different papers described that MSCs/NCSCs 
could serve as trophic mediators in diverse 
situations of tissue lesions [43, 44], which 
make their use relevant in the context of spinal 
cord damages. Indeed, several studies reported 
that MSCs/NCSCs were able to secrete 
neurotrophic factors that exhibit substantial 
effects on neuron survival and neurite 
outgrowth, in both in vitro and in vivo 
paradigms (Table 2). For instance, BMSCs 
were able to support and direct axonal growth 
of adult DRG neurons in vitro, by secreting 
extracellular matrix that orientate neurite 
extension, but especially by secreting 
molecules (as BMSCs-conditioned medium 
(BMSCs-CM) treatment generated the longest 
neurites) [45]. Besides, it was shown that 
BMSCs and BMSCs-CM (even when 
microvesicle-depleted) were able to protect 
cortical neurons against N-methyl-D-asparte 
(NMDA) excitotoxicity [46]. Unfortunately, no 
details about the precise molecules present 
inside the conditioned medium were provided. 
 
Crigler et al. identified those factors and 
showed that BMSCs secreted significant levels 
of brain-derived neurotrophic factor (BDNF) 
and nerve growth factor (NGF), thereby 
partially favoring neurite extension when co-
cultured with neuroblastoma cells or DRG 
neurons [47]. The involvement of BDNF and 
NGF were then confirmed in animal models of 
SCI. Indeed, grafts of adipose tissue-derived 
MSCs (AT-MSCs) into the injured spinal cord 
of mice improved functional recovery, in 
correlation with increased BDNF expression 
and enhanced regrowth of serotonergic fibers. 
They also noticed that improvements were 
greater compared to BMSCs transplantation 
conditions [48]. Neuronal rescue coupled with 
pathological and behavioral progresses were 
also observed after graft of BDNF-
hypersecreting-BMSCs in spinal cord-injured 
rats [49], suggesting a trophic role for grafted 
cells. NGF also seemed to be involved in SCI 
motor recovery and tissue sparing [50]. Finally, 
Hawryluk et al. showed that the expression 
levels of NGF, leukemia inhibitory factor 
(LIF), insulin-like growth factor (IGF)-1 and 
transforming growth factor (TGF)-β1 were 
significantly reduced in the rat spinal cord, 
three weeks after being compressed, and that 





intrathecal transplantation of BMSCs induced 
an up-regulation of those trophic factors [51]. 
 
2.2. Intermediate phase events: 
Inflammation, oxidative stress and apoptotic 
death of host cells 
2.2.1. Immunomodulating properties of 
MSCs/NCSCs and regulation of 
inflammation 
The immunomodulatory properties of 
MSCs/NCSCs have been associated with both 
molecule secretions and cell-cell contact. First 
of all, it was shown that MSCs/NCSCs were 
able to suppress T-cell proliferation [52] and 
monocyte maturation into dendritic cells [53]. 
Moreover, MSCs/NCSCs impaired the 
functionality of dendritic cells, their antigen-
presenting properties and cytokine secretion 
[54], and also hampered the proper function of 
natural killer cells and their interleukin (IL)-2 
secretion [55]. Many other studies also 
reported immunomodulating functions of 
MSCs/NCSCs which were of significant 
importance in graft-versus-host disease cases 
[56], and reviewed in details by Uccelli et al. 
[57], Prockop et al. [58] and Singer and Caplan 
[59]. 
 
In the past few years, several papers also 
described more precisely the 
immunomodulative properties of 
MSCs/NCSCs in the particular case of SCI 
(Table 3). Globally, all those experimental 
studies reported a potent anti-inflammatory 
action of MSCs/NCSCs when transplanted in 
spinal cord injured animals. 
 
Indeed, Seo et al. demonstrated that rats with 
contused spinal cord directly followed by 
umbilical cord blood MSCs (UCB-MSCs) 
intra-venous (IV) injection, presented 
significant improvements in motor/sensory 
score. These improvements were correlated 
with a reduction of inflammatory events, as 
both a decrease in IL-1β and IL-6 expression 
and an increase in IL-10 expression were 
observed. Moreover, the number of activated 
macrophages was reduced in those conditions 
[60]. Those results were consistent with 
previous observations from Abrams et al., 
showing that BMSCs transplantation decreased 
astrocytic reactivity and microglial activation 
inside the lesioned spinal cord, associated with 
a reduced injury-induced response to 
mechanical stimuli [61]. 
 
Still, those experiments did not provide any 
clue on the real interaction of MSCs/NCSCs 
with host cells underlying these anti-
inflammatory effects. Nakajima et al. showed 
that MSC/NCSCs transplantation into the 
epicenter of a spinal cord contusion was 
associated with a switch in host macrophage 
phenotype, from classically-activated (M1) to 
alternatively-activated (M2) [62] (which are 
known to have anti-inflammatory properties), 
and even promoted regrowth of sensory axons 
in a SCI model. This was also associated with 
an elevation of IL-4 and IL-13 levels of 
expression and reduction in IL-6 and tumor 
necrosis factor (TNF)-α levels, at the lesion 
site. All those events were correlated with a 
significant recovery of locomotor function in 
contused rats, as assessed by the Basso Beattie 
Bresnahan (BBB) scoring which appraises 
motor function, especially based on walk 
evaluation [63]. Busch et al. previously 
reported this M1 to M2 switch, while studying 
the beneficial effects of multipotent adult 
progenitor cells or MAPCs (a very immature 
BMSCs subtype) [64] on dorsal roots ganglia 
(DRG) dystrophic neurons, in vitro. Besides, 
this study also described a valuable effect of 
MAPCs transplantation on macrophage 
activation after dorsal column crush lesion, 
associated with enhanced axonal growth [65]. 
At the opposite, Hawryluk et al. demonstrated 
that intrathecal injection of BMSCs induced an 
increase in IL-1β in the epicenter of a spinal 
cord compression [51] which rather reveals an 
induction of inflammation. 
 
2.2.2.Anti-oxidative actions of 
MSCs/NCSCs. 
Free radical formation, lipid peroxidation and 
further oxidative damage events are generated 
during acute SCI and are tightly linked with 
mitochondrial dysfunctions, disruption in ion 
balance, glutamate-release and associated 
excitotoxicity. Different therapeutical 
strategies based on antioxidant compounds are 
therefore currently tested in experimental 
animal models and in clinical trial procedures. 
Unfortunately those drugs often lack in 





selectivity and trigger side effects (reviewed by 
Hall et al. [66]). Very few detailed data about 
anti-oxidant potency of stem cells are recorded 
in SCI preclinical models. Still, several in vitro 
studies provided clues on the mechanisms 
involved in the protection against oxidative 
damage and reactive oxygen species (ROS) 
(Table 3). 
 
First of all, BMSCs were reported to be able to 
efficiently manage in vitro-induced oxidative 
stress. Indeed, it was shown that cell viability 
was not altered by ROS [67], and that 
resistance to ROS was linked to glutathione 
availability. Therefore it would be conceivable 
to use BMSCs to reduce oxidative stress-
induced damages, in vivo. However, other 
studies about UCB-MSCs showed that these 
cells suffered from senescence and genomic 
alterations once undergoing oxidative stress 
[68]. 
 
In vitro tests showed that stem cells could 
protect different types of cells against oxidative 
stress. For instance, tooth-germ stem cells 
(TGSCs) are able to protect SH-SY5Y cells 
(human neuroblastoma-derived neuronal cell 
line) from amyloid-beta (Aβ) peptide or 6-
hydroxydopamine (6-OHDA)-induced cell 
death in culture, by increasing the activity of 
antioxidant proteins such as catalase, 
glutathione-peroxidase (GP) or superoxide 
dismutase (SOD) [69]. Similarly, AT-MSCs-
CM helped dermal fibroblasts to resist to free 
radicals in culture by inducing an enhancement 
of their SOD and GP activity with a decrease 
of apoptotic cells [70]. In the same line of 
evidence, Oh et al. demonstrated that the co-
culture of neural stem cells (NSCs) with AT-
MSCs protected NSCs against hydrogen 
peroxide and serum deprivation-insult, in both 
normoxia and hypoxia conditions (as showed 
by increased survival and decreased apoptosis). 
Likewise, they showed that the co-
transplantation of NSCs and AT-MSCs 
enhanced the survival of grafted NSCs inside 
the compressed spinal cord of rats [71]. 
Finally, Lin et al.’s study showed that 
neuroglobin-expressing BMSCs grafting 
improved functionality after SCI in rabbits, and 
this was associated with a decrease in lipid 
peroxidation (as assessed by reduced 
malondialdehyde levels) and decreased 
apoptotic index [72]. 
 
2.2.3.Anti-apoptotic properties of 
MSCs/NCSCs. 
Another aspect that has been quite well-
described in injured spinal cord concerns 
apoptotic events. Indeed, after SCI, post-
traumatic tissue necrosis occurs but is followed 
by apoptotic events from myelinating 
oligodendrocytes, microglial cells and neurons 
[73]. Apoptosis pathways subsequent to SCI 
imply either Fas-dependent and/or TNF-α 
signalization, followed by activation of caspase 
cascade or JNK pathway [74, 75]. 
 
As described above, different studies showed 
that MSCs/NCSCs treatment are able to lessen 
cell apoptosis, either in a SCI model or under 
unfavorable culture conditions. Dasari et al. 
characterized more accurately the diverse anti-
apoptotic actions of MSCs/NCSCs in the 
context of SCI (Table 3). They demonstrated 
the decrease of caspase-3 expression by 
oligodendrocytes and neurons, lowering the 
number of TUNEL-positive cells (TUNEL - 
Terminal deoxunucleotidyl dUTP Nick End 
Labeling – is a method to detect cells 
undergoing apoptosis) when an impacted 
spinal cord was transplanted with BMSCs. The 
expression of Fas was down-regulated in 
neural/glial cells inside the lesion site, 
triggering the decrease of caspase-8, caspase-
10 and caspase-3 activation [76]. Besides, 
BMSCs treatment up-regulated the expression 
of FLIP and XIAP (two inhibitors of apoptosis) 
and nuclear cleavage of poly [ADP-ribose] 
polymerase 1 (PARP-1) was also reduced. 
They further completed those data by 
evidencing the activity of UCB-MSCs on TNF-
α and NF-κB-mediated apoptosis pathway [77] 
and the implication of the upregulation of the 
phosphoinositide-3-kinase (PI3K)/Akt pathway 
in anti-apoptotic activity of UCB-MSCs once 
grafted in SCI rats [78]. PI3K/Akt pathway 
was also activated in embryonic neurons by 
MSCs in vitro and was associated with a 









2.3. Chronic phase events – Demyelination 
of axons and glial scar formation. 
2.3.1.Pro-myelinating abilities of 
MSCs/NCSCs. 
Different in vitro evidences established that 
MSCs are able to promote maturation of glial 
precursors into myelinating cells (Table 4). 
Indeed, BMSCs-CM primes oligodendroglial 
cell fate decision of proliferating neural 
precursors cells in vitro (assessed by A2B5, 
NG2, O4, galactocerebroside [GalC] and 2',3'-
Cyclic-nucleotide 3'-phosphodiesterase 
[CNPase] staining) by modulating Id2/Olig2 
expression [80]. This was previously observed 
in co-cultures of BMSCs with NSCs [81] and 
in co-transplantation experiments with NSCs 
on hippocampal slices [82]. Interestingly, the 
same group compared BMSCs-CM to ciliary 
neurotrophic factor (CNTF) treatment, and 
showed that if CNTF only influences 
differentiation/maturation of neural precursor 
cells into oligodendrocytes, BMSCs-CM also 
instructs cell fate decisions and commitment 
[83]. 
 
Lamina propria stem cells (LP-SCs) were 
identified to present typical BMSCs features, 
but LP-SCs or LP-SCs-CM are more efficient 
(compared to BMSCs of BMSCs-CM) to 
promote in vitro myelination of dissociated 
spinal cord neurons [84]. Additionally, LP-SCs 
and LP-SCs-CM enhanced proliferation and 
process extension of oligodendrocyte 
progenitor cells (OPCs) and olfactory 
ensheathing cells (OECs). 
 
Remyelination abilities of MSCs were further 
described in in vivo experimental models 
(Table 4). Neurotrophin-3 (NT3)-
overexpressing BMSCs were injected in a rat 
model of ethidium bromide-induced spinal 
cord demyelination [85]. The cell implantation 
was coupled to strong myelin-basic protein 
(MBP) expression in or around the 
demyelinated area. NT3-BMSCs seemed to 
participate to remyelination, but more 
specifically promoted the enrollment of 
endogenous myelinating oligodendrocytes, 
hence improving significantly locomotor 
function. Park et al. also described enhanced 
oligodendrogliogenesis inside the contused 
spinal cord of rats, once they were treated with 
UCB-MSCs [86]. 
 
Another strategy consists into differentiating 
MSCs/NCSCs into myelinating cells just 
before transplanting them inside the lesioned 
spinal cord. For instance, neuroprotection and 
motor improvements were much more drastic 
using skin-derived precursor (SKPs) or 
BMSCs previously differentiated into Schwann 
cells than non-predifferentiated cells [87, 88]. 
Indeed, results revealed that both cell types 
reduced the size of the contusion cavity, 
myelinated host axons and recruited 
endogenous Schwann cells. SKPs-derived 
Schwann cells also provided a bridge across 
the lesion site, increased the extent of spared 
tissue, promoted myelination of spared axons, 
reduced gliosis, and provided an environment 
that highly favors the axonal growth. Finally, 
SKPs/BMSCs-derived Schwann cells provided 
enhanced locomotor recovery relative to native 
cells. In the same way, co-cultivating BMSCs 
with Schwann cells improves their therapeutic 
effects when grafted in spinal cord-injured 
mice [89]. 
 
2.3.2. Degradation of extracellular matrix by 
MSCs/NCSCs. 
Matrix metalloproteinases (MMPs) are 
endopeptidases that degrade extracellular 
matrix proteins, proteinases and membrane 
receptors, and play a dual role in cases of SCI. 
After SCI, MMPs contribute to secondary 
pathogenesis by promoting inflammation, 
inducing blood-brain-barrier disruption, 
degrading myelin, etc. On the other hand, it has 
been shown that they are able to regulate 
axonal guidance and regrowth by remodeling 
the extracellular matrix [90, 91]. 
 
UCB-MSCs upregulate the expression of 
MMP-2 inside a lesion, three weeks following 
rat spinal cord contusion [92] (Table 4). The 
activity of MMP2 was increased in the treated 
spinal cords and this was coupled to a 
reduction in the glial scarring, confirming the 
already-reported beneficial effect of MMP-2 
on astrocyte reactivity, and chondroitin sulfate 
proteoglycans accumulation after SCI [93]. 
 
 





2.4. Pro-angiogenic abilities of 
MSCs/NCSCs. 
Managing blood supply and revascularization 
is mandatory for the repair of hypoxic and 
inflamed environment of spinal cord lesioned 
tissue. The secretion of pro-angiogenic factors 
such as vascular endothelial growth factor 
(VEGF) by MSCs/NCSCs could help in this 
vascular remodeling (Table 5). New blood 
vessels and enhanced blood supply could 
provide valuable help in lesion recovery 
whatever the acute, intermediate or chronic 
timing, 
 
The study of Quertainmont et al. revealed a 
higher number of blood vessels stained for rat 
endothelial cell antigen 1 (RECA-1) in the 
epicenter of spinal cord lesions after BMSCs 
graft, even if VEGF was not overexpressed in 
MSC-treated spinal cord extracts [50]. The 
same observation was reported after AT-MSCs 
transplantation inside acutely injured spinal 
cord, as assessed by the higher number of von 
Willebrand Factor (vWF)-positive blood 
vessels (which was superior compared to 
BMSC transplantation conditions) [48]. 
 
Oh et al. showed that AT-MSCs enhanced 
vasculogenesis after being transplanted in the 
lesion-epicenter of spinal cord injured rats 
[94]. Moreover, the vWF, CD31 or smooth 
muscle actin (SMA)-positive areas were 
especially higher when the AT-MSC were 
transplanted as a 3D-cell mass (inserted in 
maltose-binding protein-fibroblast-growth 
factor 2 surface). 
 
The same concept of 3D-cluster was used by 
Zeng et al., who removed a segment of the 
spinal cord of rats and replaced it by a gelatin 
sponge scaffold containing BMSC. They 
observed that regenerated blood vessels 
crossed the junction between host spinal cord 
tissue and scaffold. vWF-positive area was also 
higher in those conditions compared with a 
scaffold without cells. They also showed that 
MSC-surrounding blood vessels expressed 







Traumatic spinal cord injuries represent a 
critical issue in clinical situation nowadays, 
and injured patients undergo severe 
physiological, psychological and social 
failures. Even if slight recovery can be 
achieved with intensive training programs and 
treatments, this recuperation is slow and 
limited, and depends on the degree of injury. 
 
Cell-based therapies could consequently 
provide additional expectations in the case of 
spinal cord lesions. Recent remarkable papers 
reviewed the interest of stem cell therapy in 
spinal cord injuries and other neurological 
diseases, from experimental models to clinical 
application (iPS cells and ES cells [42, 96, 97]; 
MSCs [98-100]; comparison of diverse types 
of stem cells [101-103]). 
 
However, after considering all those papers 
that were somehow informative about several 
aspects of stem cell therapies, we wanted to dig 
deeper about the precise mechanisms of stem 
cell-associated positive effects, and more 
particularly stromal stem cells. Indeed, as 
initially mentioned, we are convinced that 
MSCs and NCSCs, both isolated from adult 
bone marrow could constitute a great tool for 
stem cell therapy and we will discuss their 
advantages thereafter. 
 
In the past few years, several prospective 
clinical trials confirmed that AT-MSC or 
BMSC transplantation in spinal cord injured-
patients did not induce tumors or any other side 
effects, but promoted preliminary motor and 
somatosensory improvements, which still have 
to be confirmed with further investigations in 
randomized trials, at a larger scale [19, 104, 
105]. Nonetheless, it seems that those clinical 
analyses were somewhat prematurely executed. 
Indeed, the exact(s) way(s) by which those 
stem cells exert their beneficial effects are not 
fully understood and still need to be 
characterized. 
 
All experimental data described in this review 
summarized the diverse properties of adult 
mesenchymal or neural crest stem cells that 





could be relevant in spinal cord injury context 
Still, is has to be highlighted that (Figure 2): 
 
(1) BMSCs could modulate immune response 
and inflammatory reaction after SCI by 
adjusting cytokine secretion and macrophage 
activation, resulting in a potent anti-
inflammatory effect for the most part. This 
inflammatory modulation has been observed 
also for AT-MSCs and UCB-MSCs suggesting 
that these effects should be attributed to the 
presence of MSCs, rather than NCSCs, as no 
NCSC has ever been identified in adipose 
tissue or umbilical cord blood so far. 
 
(2) BMSCs also protect cells against oxidative 
damage by increasing the expression of 
antioxidant proteins such as glutathione-
associated enzymes, catalase and superoxide 
dismutase. All those neuroprotective activities 
are obviously associated with a decrease in 
apoptotic events, which appear to be mediated 
through different pathways (Caspases, PI3K, 
Akt…), and well regulated by stem cell graft. 
 
(3) Besides inducing this newly favorable 
lesion environment, MSCs are also able to 
promote axonal sparing and sprouting of new 
neurites, by means of neurotrophic support and 
efficient remyelination of fibers. The formation 
of new myelin sheaths can be both due to 
recruited endogenous glial cells and to 
transplanted BMSCq themselves. Interestingly, 
this last characteristic has only been 
demonstrated for BMSC or SKPs. As both 
populations contain NCSCs, it is tempting to 
suggest that this last property could be 
attributed to those cells. 
 
To the light of those observations, it appears 
that MSCs and NCSCs could be used 
concomitantly: 1) MSCs could be injected in 
acute phasis to modulate inflammation, 
whereas NCSCs could then be injected in 
chronic phasis to improve neuronal recovery 
and axonal sprouting. Adult MSCs/NCSCs 
present enormous interest regarding SCI 
therapy and could efficiently regulate a 
multitude of phenomena occurring at the time 
of a lesion. Moreover, it is interesting to 
highlight that both cell types could be isolated 
from the same patient, limiting the risk of 
immune reaction in case of heterologous graft. 
 
Nonetheless, we think that this wide-ranging 
beneficial effect of MSCs/NCSCs lacks in 
systematic and mechanistic explanations. 
Although the different molecules that are 
secreted by MSCs were largely studied and 
identified in vitro (for example in conditioned 
medium analyses) [106], details are missing 
about the genuine mechanisms by which the 
physiopathological and clinical recovery of 
experimental SCI animals are achieved. 
 
A common criticism concerning BMSCs is the 
lack of reproducibility. Therefore, several 
points have to be taken into consideration: 1) 
Donor age: It appears that for human above 30 
years old, MSCs have a drastically decreased 
secreting factors and stemness characteristics 
[107, 108]. It is therefore suggested to use 
MSCs from young donors, excluding 
autologous graft for oldest patients. 2) MSC 
and NCSC isolation protocols: since NCSCs 
are systematically mistaken for MSCs, new 
specific panels of MSC or NCSC markers 
should be defined. Indeed, all CD markers 
classically defined by the International Society 
for Cellular Therapy to characterize clinical 
grade MSCs [109] are not specific enough to 
discriminate NCSCs. Similarly, technical 
questions remain regarding the design of 
MSCs/NCSCs transplantation and its 
procedural parameters. 3) Technical questions 
remain regarding the design of MSCs/NCSCs 
transplantation and its procedural parameters. 
(a) The finest way to implant cells still needs to 
be defined. It was recently published that 
intracisternal transplantation of BMSCs led to 
the best motor recovery in rats, followed by 
intralesional and intravenous administration 
[110], while another study described the same 
functional improvement after intralesional or 
intravenous cell injection [111]. (b) The impact 
of immunosuppressive treatment has to be 
evaluated, in order to allow or prevent 
allografts. (c) The right timing of injection 
should be identified, as well as the importance 
of SCI kinetics on the transplantation time. As 
suggested above, injection of MSCs in acute 
phasis, then NCSCs in chronic phasis might be 
the right protocol. (d) Finally, the maturation 





state of transplanted stem cells should be 
characterized. As several studies use stem cells 
under their initial state; other papers have used 
pre-differentiated cells in SCI models. Both 
neuron-differentiated and glia-differentiated 
cells have shown valuable benefits in 
experimental animals. Questions also remain 
concerning cell culture conditions before 
grafting: confluence, number of passages, etc. 
All those technical issues should be deeply 
studied in order to answer these questions and 
develop better strategies for cell therapy 
protocols. 
 
In conclusion, as recently suggested by Vawda 
and Fehlings [112], the explosion in the 
number of studies examining the secretomes of 
stromal cells as well as the number of 
submitted patent reflect a recognition by the 
scientific communities of the vastly untapped 
potential of MSCs/NCSCs, however, evidence 
on mechanistic organization and technical 
procedures should be provided in order to 
ensure efficient and accurate cell-therapy 




This work was supported by a grant from the 
Fonds National de la Recherche Scientifique 
(FNRS) of Belgium, by the Belgian League 
against Multiple Sclerosis associated with the 
Leon Frédericq Foundation and by the Fonds 
Spéciaux à la Recherche of the University of 
Liège. 
 
4. Disclosure of potential conflicts of interest 







1. Friedenstein AJ. Stromal mechanisms of bone 
marrow: cloning in vitro and retransplantation in 
vivo. Haematol Blood Transfus. 1980;25:19-29. 
2. Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. 
Precursors for fibroblasts in different populations of 
hematopoietic cells as detected by the in vitro colony 
assay method. Exp Hematol. 1974;2:83-92. 
3. Bianco P, Riminucci M, Gronthos S, et al. Bone 
marrow stromal stem cells: nature, biology, and 
potential applications. Stem Cells. 2001;19:180-192. 
4. Pittenger MF, Mackay AM, Beck SC, et al. 
Multilineage potential of adult human mesenchymal 
stem cells. Science. 1999;284:143-147. 
5. Zuk PA, Zhu M, Ashjian P, et al. Human adipose 
tissue is a source of multipotent stem cells. Mol Biol 
Cell. 2002;13:4279-4295. 
6. Dellavalle A, Sampaolesi M, Tonlorenzi R, et al. 
Pericytes of human skeletal muscle are myogenic 
precursors distinct from satellite cells. Nat Cell Biol. 
2007;9:255-267. 
7. Fan J, Varshney RR, Ren L, et al. Synovium-derived 
mesenchymal stem cells: a new cell source for 
musculoskeletal regeneration. Tissue Eng Part B 
Rev. 2009;15:75-86. 
8. Caplan AI, Correa D. The MSC: an injury drugstore. 
Cell Stem Cell. 2011;9:11-15. 
9. Erices A, Conget P, Minguell JJ. Mesenchymal 
progenitor cells in human umbilical cord blood. Br J 
Haematol. 2000;109:235-242. 
10. Wang HS, Hung SC, Peng ST, et al. Mesenchymal 
stem cells in the Wharton's jelly of the human 
umbilical cord. Stem Cells. 2004;22:1330-1337. 
11. Sessarego N, Parodi A, Podesta M, et al. Multipotent 
mesenchymal stromal cells from amniotic fluid: solid 
perspectives for clinical application. Haematologica. 
2008;93:339-346. 
12. Yen BL, Huang HI, Chien CC, et al. Isolation of 
multipotent cells from human term placenta. Stem 
Cells. 2005;23:3-9. 
13. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, et al. 
Adult bone marrow stromal cells differentiate into 
neural cells in vitro. Exp Neurol. 2000;164:247-256. 
14. Wislet-Gendebien S, Hans G, Leprince P, et al. 
Plasticity of cultured mesenchymal stem cells: switch 
from nestin-positive to excitable neuron-like 
phenotype. Stem Cells. 2005;23:392-402. 
15. Morikawa S, Mabuchi Y, Niibe K, et al. 
Development of mesenchymal stem cells partially 
originate from the neural crest. Biochem Biophys 
Res Commun. 2009;379:1114-1119. 
16. Prockop DJ, Oh JY. Medical therapies with adult 
stem/progenitor cells (MSCs): a backward journey 
from dramatic results in vivo to the cellular and 
molecular explanations. J Cell Biochem. 
2012;113:1460-1469. 
17. Neirinckx V, Coste C, Rogister B, et al. Concise 
review: adult mesenchymal stem cells, adult neural 
crest stem cells, and therapy of neurological 
pathologies: a state of play. Stem Cells Transl Med. 
2013;2:284-296. 
18. Bracken MB. Methylprednisolone in the 
management of acute spinal cord injuries. Med J 
Aust. 1990;153:368. 
19. Karamouzian S, Nematollahi-Mahani SN, Nakhaee 
N, et al. Clinical safety and primary efficacy of bone 
marrow mesenchymal cell transplantation in 





subacute spinal cord injured patients. Clin Neurol 
Neurosurg. 2012;114:935-939. 
20. Wislet-Gendebien S, Laudet E, Neirinckx V, et al. 
Mesenchymal stem cells and neural crest stem cells 
from adult bone marrow: characterization of their 
surprising similarities and differences. Cell Mol Life 
Sci. 2012;69:2593-2608. 
21. Neirinckx V, Marquet A, Coste C, et al. Adult Bone 
Marrow Neural Crest Stem Cells and Mesenchymal 
Stem Cells Are Not Able to Replace Lost Neurons in 
Acute MPTP-Lesioned Mice. PLoS One. 
2013;8:e64723. 
22. Achilleos A, Trainor PA. Neural crest stem cells: 
discovery, properties and potential for therapy. Cell 
Res. 2012;22:288-304. 
23. Nagoshi N, Shibata S, Kubota Y, et al. Ontogeny and 
multipotency of neural crest-derived stem cells in 
mouse bone marrow, dorsal root ganglia, and 
whisker pad. Cell Stem Cell. 2008;2:392-403. 
24. Glejzer A, Laudet E, Leprince P, et al. Wnt1 and 
BMP2: two factors recruiting multipotent neural 
crest progenitors isolated from adult bone marrow. 
Cell Mol Life Sci. 2011;68:2101-2114. 
25. Fernandes KJ, McKenzie IA, Mill P, et al. A dermal 
niche for multipotent adult skin-derived precursor 
cells. Nat Cell Biol. 2004;6:1082-1093. 
26. Toma JG, McKenzie IA, Bagli D, et al. Isolation and 
characterization of multipotent skin-derived 
precursors from human skin. Stem Cells. 
2005;23:727-737. 
27. Hu YF, Zhang ZJ, Sieber-Blum M. An epidermal 
neural crest stem cell (EPI-NCSC) molecular 
signature. Stem Cells. 2006;24:2692-2702. 
28. Kruger GM, Mosher JT, Bixby S, et al. Neural crest 
stem cells persist in the adult gut but undergo 
changes in self-renewal, neuronal subtype potential, 
and factor responsiveness. Neuron. 2002;35:657-669. 
29. Gronthos S, Mankani M, Brahim J, et al. Postnatal 
human dental pulp stem cells (DPSCs) in vitro and in 
vivo. Proc Natl Acad Sci U S A. 2000;97:13625-
13630. 
30. Miura M, Gronthos S, Zhao M, et al. SHED: stem 
cells from human exfoliated deciduous teeth. Proc 
Natl Acad Sci U S A. 2003;100:5807-5812. 
31. Tomita Y, Matsumura K, Wakamatsu Y, et al. 
Cardiac neural crest cells contribute to the dormant 
multipotent stem cell in the mammalian heart. J Cell 
Biol. 2005;170:1135-1146. 
32. Widera D, Zander C, Heidbreder M, et al. Adult 
palatum as a novel source of neural crest-related 
stem cells. Stem Cells. 2009;27:1899-1910. 
33. Yoshida S, Shimmura S, Nagoshi N, et al. Isolation 
of multipotent neural crest-derived stem cells from 
the adult mouse cornea. Stem Cells. 2006;24:2714-
2722. 
34. Barraud P, Seferiadis AA, Tyson LD, et al. Neural 
crest origin of olfactory ensheathing glia. Proc Natl 
Acad Sci U S A. 2010;107:21040-21045. 
35. Suzuki J, Yoshizaki K, Kobayashi T, et al. Neural 
crest-derived horizontal basal cells as tissue stem 
cells in the adult olfactory epithelium. Neurosci Res. 
2013;75:112-120. 
36. Tome M, Lindsay SL, Riddell JS, et al. Identification 
of nonepithelial multipotent cells in the embryonic 
olfactory mucosa. Stem Cells. 2009;27:2196-2208. 
37. Mujtaba T, Mayer-Proschel M, Rao MS. A common 
neural progenitor for the CNS and PNS. Dev Biol. 
1998;200:1-15. 
38. Sieber-Blum M, Hu Y. Epidermal neural crest stem 
cells (EPI-NCSC) and pluripotency. Stem Cell Rev. 
2008;4:256-260. 
39. Lee BB, Cripps RA, Fitzharris M, et al. The global 
map for traumatic spinal cord injury epidemiology: 
update 2011, global incidence rate. Spinal Cord. 
2013. 
40. Spinal cord injury facts and figures at a glance. The 
journal of spinal cord medicine. 2012;35:480-481. 
41. Oyinbo CA. Secondary injury mechanisms in 
traumatic spinal cord injury: a nugget of this multiply 
cascade. Acta Neurobiol Exp (Wars). 2011;71:281-
299. 
42. Ronaghi M, Erceg S, Moreno-Manzano V, et al. 
Challenges of stem cell therapy for spinal cord 
injury: human embryonic stem cells, endogenous 
neural stem cells, or induced pluripotent stem cells? 
Stem Cells. 2010;28:93-99. 
43. Caplan AI, Dennis JE. Mesenchymal stem cells as 
trophic mediators. J Cell Biochem. 2006;98:1076-
1084. 
44. Phinney DG, Hill K, Michelson C, et al. Biological 
activities encoded by the murine mesenchymal stem 
cell transcriptome provide a basis for their 
developmental potential and broad therapeutic 
efficacy. Stem Cells. 2006;24:186-198. 
45. Fuhrmann T, Montzka K, Hillen LM, et al. Axon 
growth-promoting properties of human bone marrow 
mesenchymal stromal cells. Neurosci Lett. 
2010;474:37-41. 
46. Voulgari-Kokota A, Fairless R, Karamita M, et al. 
Mesenchymal stem cells protect CNS neurons 
against glutamate excitotoxicity by inhibiting 
glutamate receptor expression and function. Exp 
Neurol. 2012;236:161-170. 
47. Crigler L, Robey RC, Asawachaicharn A, et al. 
Human mesenchymal stem cell subpopulations 
express a variety of neuro-regulatory molecules and 
promote neuronal cell survival and neuritogenesis. 
Exp Neurol. 2006;198:54-64. 
48. Zhou Z, Chen Y, Zhang H, et al. Comparison of 
mesenchymal stromal cells from human bone 
marrow and adipose tissue for the treatment of spinal 
cord injury. Cytotherapy. 2013;15:434-448. 
49. Sasaki M, Radtke C, Tan AM, et al. BDNF-
hypersecreting human mesenchymal stem cells 
promote functional recovery, axonal sprouting, and 
protection of corticospinal neurons after spinal cord 
injury. J Neurosci. 2009;29:14932-14941. 
50. Quertainmont R, Cantinieaux D, Botman O, et al. 
Mesenchymal Stem Cell Graft Improves Recovery 
after Spinal Cord Injury in Adult Rats through 
Neurotrophic and Pro-Angiogenic Actions. PLoS 
One. 2012;7:e39500. 
51. Hawryluk GW, Mothe A, Wang J, et al. An in vivo 
characterization of trophic factor production 





following neural precursor cell or bone marrow 
stromal cell transplantation for spinal cord injury. 
Stem Cells Dev. 2012;21:2222-2238. 
52. Bartholomew A, Sturgeon C, Siatskas M, et al. 
Mesenchymal stem cells suppress lymphocyte 
proliferation in vitro and prolong skin graft survival 
in vivo. Exp Hematol. 2002;30:42-48. 
53. Jiang XX, Zhang Y, Liu B, et al. Human 
mesenchymal stem cells inhibit differentiation and 
function of monocyte-derived dendritic cells. Blood. 
2005;105:4120-4126. 
54. Aggarwal S, Pittenger MF. Human mesenchymal 
stem cells modulate allogeneic immune cell 
responses. Blood. 2005;105:1815-1822. 
55. Spaggiari GM, Capobianco A, Becchetti S, et al. 
Mesenchymal stem cell-natural killer cell 
interactions: evidence that activated NK cells are 
capable of killing MSCs, whereas MSCs can inhibit 
IL-2-induced NK-cell proliferation. Blood. 
2006;107:1484-1490. 
56. Le Blanc K, Rasmusson I, Sundberg B, et al. 
Treatment of severe acute graft-versus-host disease 
with third party haploidentical mesenchymal stem 
cells. Lancet. 2004;363:1439-1441. 
57. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem 
cells in health and disease. Nat Rev Immunol. 
2008;8:726-736. 
58. Prockop DJ, Oh JY. Mesenchymal stem/stromal 
cells (MSCs): role as guardians of inflammation. Mol 
Ther. 2012;20:14-20. 
59. Singer NG, Caplan AI. Mesenchymal stem cells: 
mechanisms of inflammation. Annu Rev Pathol. 
2011;6:457-478. 
60. Seo JH, Jang IK, Kim H, et al. Early 
Immunomodulation by Intravenously Transplanted 
Mesenchymal Stem Cells Promotes Functional 
Recovery in Spinal Cord Injured Rats. Cell 
Medicine. 2011;2:55-67. 
61. Abrams MB, Dominguez C, Pernold K, et al. 
Multipotent mesenchymal stromal cells attenuate 
chronic inflammation and injury-induced sensitivity 
to mechanical stimuli in experimental spinal cord 
injury. Restor Neurol Neurosci. 2009;27:307-321. 
62. Kigerl KA, Gensel JC, Ankeny DP, et al. 
Identification of two distinct macrophage subsets 
with divergent effects causing either neurotoxicity or 
regeneration in the injured mouse spinal cord. J 
Neurosci. 2009;29:13435-13444. 
63. Nakajima H, Uchida K, Guerrero AR, et al. 
Transplantation of mesenchymal stem cells promotes 
an alternative pathway of macrophage activation and 
functional recovery after spinal cord injury. J 
Neurotrauma. 2012;29:1614-1625. 
64. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. 
Pluripotency of mesenchymal stem cells derived 
from adult marrow. Nature. 2002;418:41-49. 
65. Busch SA, Hamilton JA, Horn KP, et al. Multipotent 
adult progenitor cells prevent macrophage-mediated 
axonal dieback and promote regrowth after spinal 
cord injury. J Neurosci. 2011;31:944-953. 
66. Hall ED. Antioxidant therapies for acute spinal cord 
injury. Neurotherapeutics. 2011;8:152-167. 
67. Valle-Prieto A, Conget PA. Human mesenchymal 
stem cells efficiently manage oxidative stress. Stem 
Cells Dev. 2010;19:1885-1893. 
68. Ko E, Lee KY, Hwang DS. Human umbilical cord 
blood-derived mesenchymal stem cells undergo 
cellular senescence in response to oxidative stress. 
Stem Cells Dev. 2012;21:1877-1886. 
69. Yalvac ME, Yarat A, Mercan D, et al. 
Characterization of the secretome of human tooth 
germ stem cells (hTGSCs) reveals neuro-protection 
by fine-tuning micro-environment. Brain Behav 
Immun. 2013. 
70. Kim WS, Park BS, Kim HK, et al. Evidence 
supporting antioxidant action of adipose-derived 
stem cells: protection of human dermal fibroblasts 
from oxidative stress. J Dermatol Sci. 2008;49:133-
142. 
71. Oh JS, Kim KN, An SS, et al. Cotransplantation of 
mouse neural stem cells (mNSCs) with adipose 
tissue-derived mesenchymal stem cells improves 
mNSC survival in a rat spinal cord injury model. Cell 
Transplant. 2011;20:837-849. 
72. Lin WP, Chen XW, Zhang LQ, et al. Effect of 
neuroglobin genetically modified bone marrow 
mesenchymal stem cells transplantation on spinal 
cord injury in rabbits. PLoS One. 2013;8:e63444. 
73. Crowe MJ, Bresnahan JC, Shuman SL, et al. 
Apoptosis and delayed degeneration after spinal cord 
injury in rats and monkeys. Nat Med. 1997;3:73-76. 
74. Yu WR, Liu T, Fehlings TK, et al. Involvement of 
mitochondrial signaling pathways in the mechanism 
of Fas-mediated apoptosis after spinal cord injury. 
Eur J Neurosci. 2009;29:114-131. 
75. Nakahara S, Yone K, Sakou T, et al. Induction of 
apoptosis signal regulating kinase 1 (ASK1) after 
spinal cord injury in rats: possible involvement of 
ASK1-JNK and -p38 pathways in neuronal 
apoptosis. J Neuropathol Exp Neurol. 1999;58:442-
450. 
76. Dasari VR, Spomar DG, Cady C, et al. Mesenchymal 
stem cells from rat bone marrow downregulate 
caspase-3-mediated apoptotic pathway after spinal 
cord injury in rats. Neurochem Res. 2007;32:2080-
2093. 
77. Dasari VR, Veeravalli KK, Tsung AJ, et al. Neuronal 
apoptosis is inhibited by cord blood stem cells after 
spinal cord injury. J Neurotrauma. 2009;26:2057-
2069. 
78. Dasari VR, Spomar DG, Li L, et al. Umbilical cord 
blood stem cell mediated downregulation of fas 
improves functional recovery of rats after spinal cord 
injury. Neurochem Res. 2008;33:134-149. 
79. Isele NB, Lee HS, Landshamer S, et al. Bone 
marrow stromal cells mediate protection through 
stimulation of PI3-K/Akt and MAPK signaling in 
neurons. Neurochem Int. 2007;50:243-250. 
80. Steffenhagen C, Dechant FX, Oberbauer E, et al. 
Mesenchymal stem cells prime proliferating adult 
neural progenitors toward an oligodendrocyte fate. 
Stem Cells Dev. 2012;21:1838-1851. 
81. Rivera FJ, Couillard-Despres S, Pedre X, et al. 
Mesenchymal stem cells instruct oligodendrogenic 





fate decision on adult neural stem cells. Stem Cells. 
2006;24:2209-2219. 
82. Rivera FJ, Siebzehnrubl FA, Kandasamy M, et al. 
Mesenchymal stem cells promote oligodendroglial 
differentiation in hippocampal slice cultures. Cell 
Physiol Biochem. 2009;24:317-324. 
83. Rivera FJ, Kandasamy M, Couillard-Despres S, et al. 
Oligodendrogenesis of adult neural progenitors: 
differential effects of ciliary neurotrophic factor and 
mesenchymal stem cell derived factors. J 
Neurochem. 2008;107:832-843. 
84. Lindsay SL, Johnstone SA, Mountford JC, et al. 
Human mesenchymal stem cells isolated from 
olfactory biopsies but not bone enhance CNS 
myelination in vitro. Glia. 2013;61:368-382. 
85. Zhang YJ, Zhang W, Lin CG, et al. Neurotrophin-3 
gene modified mesenchymal stem cells promote 
remyelination and functional recovery in the 
demyelinated spinal cord of rats. J Neurol Sci. 
2012;313:64-74. 
86. Park SI, Lim JY, Jeong CH, et al. Human umbilical 
cord blood-derived mesenchymal stem cell therapy 
promotes functional recovery of contused rat spinal 
cord through enhancement of endogenous cell 
proliferation and oligogenesis. J Biomed Biotechnol. 
2012;2012:362473. 
87. Biernaskie J, Sparling JS, Liu J, et al. Skin-derived 
precursors generate myelinating Schwann cells that 
promote remyelination and functional recovery after 
contusion spinal cord injury. J Neurosci. 
2007;27:9545-9559. 
88. Kamada T, Koda M, Dezawa M, et al. 
Transplantation of human bone marrow stromal cell-
derived Schwann cells reduces cystic cavity and 
promotes functional recovery after contusion injury 
of adult rat spinal cord. Neuropathology. 2011;31:48-
58. 
89. Xu X, Geremia N, Bao F, et al. Schwann cell 
coculture improves the therapeutic effect of bone 
marrow stromal cells on recovery in spinal cord-
injured mice. Cell Transplant. 2011;20:1065-1086. 
90. Zhang H, Chang M, Hansen CN, et al. Role of 
matrix metalloproteinases and therapeutic benefits of 
their inhibition in spinal cord injury. 
Neurotherapeutics. 2011;8:206-220. 
91. Duchossoy Y, Horvat JC, Stettler O. MMP-related 
gelatinase activity is strongly induced in scar tissue 
of injured adult spinal cord and forms pathways for 
ingrowing neurites. Mol Cell Neurosci. 2001;17:945-
956. 
92. Veeravalli KK, Dasari VR, Tsung AJ, et al. Human 
umbilical cord blood stem cells upregulate matrix 
metalloproteinase-2 in rats after spinal cord injury. 
Neurobiol Dis. 2009;36:200-212. 
93. Hsu JY, McKeon R, Goussev S, et al. Matrix 
metalloproteinase-2 facilitates wound healing events 
that promote functional recovery after spinal cord 
injury. J Neurosci. 2006;26:9841-9850. 
94. Oh JS, Park IS, Kim KN, et al. Transplantation of an 
adipose stem cell cluster in a spinal cord injury. 
Neuroreport. 2012;23:277-282. 
95. Zeng X, Zeng YS, Ma YH, et al. Bone marrow 
mesenchymal stem cells in a three-dimensional 
gelatin sponge scaffold attenuate inflammation, 
promote angiogenesis, and reduce cavity formation 
in experimental spinal cord injury. Cell Transplant. 
2011;20:1881-1899. 
96. Lukovic D, Moreno Manzano V, Stojkovic M, et al. 
Concise review: human pluripotent stem cells in the 
treatment of spinal cord injury. Stem Cells. 
2012;30:1787-1792. 
97. Nakamura M, Okano H. Cell transplantation 
therapies for spinal cord injury focusing on induced 
pluripotent stem cells. Cell Res. 2013;23:70-80. 
98. Joyce N, Annett G, Wirthlin L, et al. Mesenchymal 
stem cells for the treatment of neurodegenerative 
disease. Regen Med. 2010;5:933-946. 
99. Uccelli A, Laroni A, Freedman MS. Mesenchymal 
stem cells for the treatment of multiple sclerosis and 
other neurological diseases. Lancet Neurol. 
2011;10:649-656. 
100. Wright KT, El Masri W, Osman A, et al. 
Concise review: Bone marrow for the treatment of 
spinal cord injury: mechanisms and clinical 
applications. Stem Cells. 2011;29:169-178. 
101. Mothe AJ, Tator CH. Advances in stem cell 
therapy for spinal cord injury. J Clin Invest. 
2012;122:3824-3834. 
102. Gogel S, Gubernator M, Minger SL. Progress 
and prospects: stem cells and neurological diseases. 
Gene Ther. 2011;18:1-6. 
103. Tetzlaff W, Okon EB, Karimi-Abdolrezaee S, 
et al. A systematic review of cellular transplantation 
therapies for spinal cord injury. J Neurotrauma. 
2011;28:1611-1682. 
104. Ra JC, Shin IS, Kim SH, et al. Safety of 
intravenous infusion of human adipose tissue-derived 
mesenchymal stem cells in animals and humans. 
Stem Cells Dev. 2011;20:1297-1308. 
105. Pal R, Venkataramana NK, Bansal A, et al. Ex 
vivo-expanded autologous bone marrow-derived 
mesenchymal stromal cells in human spinal cord 
injury/paraplegia: a pilot clinical study. Cytotherapy. 
2009;11:897-911. 
106. Cantinieaux D, Quertainmont R, Blacher S, et 
al. Conditioned medium from bone marrow-derived 
mesenchymal stem cells improves recovery after 
spinal cord injury in rats: an original strategy to 
avoid cell transplantation. PLoS One. 
2013;8:e69515. 
107. Wang J, Liao L, Wang S, et al. Cell therapy 
with autologous mesenchymal stem cells-how the 
disease process impacts clinical considerations. 
Cytotherapy. 2013;15:893-904. 
108. Brohlin M, Kingham PJ, Novikova LN, et al. 
Aging effect on neurotrophic activity of human 
mesenchymal stem cells. PLoS One. 2012;7:e45052. 
109. Dominici M, Le Blanc K, Mueller I, et al. 
Minimal criteria for defining multipotent 
mesenchymal stromal cells. The International 
Society for Cellular Therapy position statement. 
Cytotherapy. 2006;8:315-317. 





110. Shin DA, Kim JM, Kim HI, et al. Comparison 
of functional and histological outcomes after 
intralesional, intracisternal, and intravenous 
transplantation of human bone marrow-derived 
mesenchymal stromal cells in a rat model of spinal 
cord injury. Acta Neurochir (Wien). 2013. 
111. Kim JW, Ha KY, Molon JN, et al. Bone 
marrow-derived mesenchymal stem cell 
transplantation for chronic spinal cord injury in rats: 
comparative study between intralesional and 
intravenous transplantation. Spine (Phila Pa 1976). 
2013;38:E1065-1074. 
112. Vawda R, Fehlings MG. Mesenchymal cells in 
the treatment of spinal cord injury: current & future 
perspectives. Curr Stem Cell Res Ther. 2013;8:25-
38. 





Figure 1. Physiopathological events occurring after spinal cord injury, contributing to the harmful 
environment that hampers axonal regrowth and recovery. 
 
 





Figure 2. Adult MSCs/NCSCs properties and the different ways they can contribute to functional 
recovery after spinal cord injury. 
 
 





Table 1: MSCs and NCSCs in adult and perinatal tissues: AT-MSCs: Adipose tissue 
mesenchymal stem cells, BMSCs: bone marrow stromal cells, DPSCs: Dental pulp stem cells; EPI-
NCSCs: Epidermal neural crest stem cells; HBCs: Horizontal basal cells; LP-NCSC: Lamina 
propria neural crest stem cells; OECs: Olfactory ensheating cells; SHED: Stem cells from human 
exfoliated deciduous teeth; SKPs: Skin-derived precursors; UCB-MSCs: Umbilical cord blood 
mesenchymal stem cells 
 
 





Table 2: ACUTE PHASE EVENTS - Neurotrophic properties of MSCs/NCSCs, axonal 
regrowth and protection against excitotoxicity. 5-HT: 5-hydroxytryptamine (serotonin): AT-
MSC: Adipose tissue mesenchymal stem cells; BBB : Beattie Basso Bresnahan; BDNF : Brain-
derived neurotrophic factor; BMSC : Bone marrow stromal cells; CM : Conditioned medium; CSF: 
Cerebrospinal fluid; CST: Corticospinal tract; DC: Dorsal column; DRG : Dorsal root ganglion;  
GFAP: Glial fibrillary acidic protein; h :  Human; IGF: Insulin-like growth factor; IL : Interleukin; 
IV : intravenous; Leukemia inhibitory factor; MΦ : Macrophages; NGF: Nerve growth factor; NF : 
Neurofilament; NMDA: N-methyl-D-aspartate; NMDAR : NMDA receptor; PDGF: Platelet-
derived growth factor; PKC: Protein kinase C; r : Rat; RECA-1: Rat endothelial cell antigen 1; 
RST: Rubrospinal tract; SC : Spinal cord; T: Thoracic; vWF: von Willebrand factor 
 
 





Table 3: INTERMEDIATE PHASE EVENTS– Immunomodulation, regulation of 
inflammation, anti-oxidative and anti-apoptotic abilities of MSCs/NCSCs. 
6-OHDA: 6-hydroxydopamine; Aβ: Amyloid peptide β; AT-MSC: Adipose tissue mesenchymal 
stem cells; Bad: Bcl- 2 associated death promoter; Bak: Bcl-2 homologous antagonist/killer; Bax: 
B-cell lymphoma 2-associated X protein; BBB : Beattie Basso Bresnahan; Bcl-…: B-cell 
lymphoma ... ; Bid;-: BH3 interacting-domain death agonist ; Bik: Bcl-2 interacting killer; BMSC : 
Bone marrow stromal cells; C: Cervical; Casp: Caspase; CAT: Catalase; CM: conditioned medium; 
CSF : Cerebrospinal fluid; DC: Dorsal column; DRG : Dorsal root ganglion;  eGFP: enhanced 
green fluorescent protein; ERK: Extreacellular signal-regulated kinase; FLIP : FLICE-inhibitory 
protein ; g: Gerbil;  GFAP: Glial fibrillary acidic protein; GPX: Gluthatione peroxidase;  GST: 
Gluthathione-s-transferase; h :  Human; Iba1: Ionized calcium-binding adapter molecule 1; IGF: 
Insulin-like growth factor; IL : Interleukin; iNOS: inducible nitric oxide synthase; IV : intravenous; 
; LIF : Leukemia inhibitory factor; MΦ : Macrophages; MAPC : multipotent adult progenitor cells; 
MAPK: Mitogen-activated protein kinase; MDA : malondialdehyde ; NGF: Nerve growth factor; 
NSC: Neural stem cells; p53 : protein 53 ; PARP-1: Poly [ADP-ribose] polymerase 1 ; PDGF: 
Platelet-derived growth factor; r : Rat; SC : Spinal cord; SSEP: Somato-sensory evoked potentials; 
SOD: Superoxide dismutase; T: Thoracic; tbOOH: tert-butyl hydroperoxide; TGSC: Tooth germ 
stem cells; TNF: Tumor necrosis factor; TNFR: TNF receptor; TUNEL: Terminal 
deoxynucleotidyl transferase dUTP nick end labeling; UCB-MSC : Umbilical cord blood 
mesenchymal stem cells; WM: White matter ; XIAP: X-linked inhibitor of apoptosis protein 











Table 4: CHRONIC PHASE EVENTS - Pro-myelinating properties and matrix-degrading 
actions of MSCs/NCSCs for promoting axonal regrowth. 
5-HT: 5-hydroxytryptamine (serotonin); APC: Adenomatous popyposis coli; BBB : Beattie Basso 
Bresnahan; BMSC : Bone marrow stromal cells; CA: Cornu ammonis; Caspr: Contactin-associated 
protein; CM : Conditioned medium; CNPase: 2',3'-Cyclic-nucleotide 3'-phosphodiesterase; DC: 
Dorsal column; DG: Dentate gyrus; DRG : Dorsal root ganglion;  EtBr: Ethidium bromide; 
GAP43: Growth-associated protein 43; GFAP: Glial fibrillary acidic protein; h :  Human; Id2 : 
Inhibitor of DNA-binding protein 2 ; LP-MSCs: Lamina propria mesenchymal stem cells; MBP : 
Myelin basic protein ; MMP: matrix metalloproteinase; NF : Neurofilament; NPC: Neural 
precursor cells; NSC: Neural stem cells; NT-3: Neurotrophin 3; OEC: Olfactory ensheating cells; 
Olig2 : Oligodendrocyte transcription factor 2 ; OPC: Oligodendrocyte precursor cells; P0 : Protein 
0; r : Rat; RIP : Receptor interaction protein; SC : Spinal cord; SCEP: Spinal cord evoked 
potentials; SKP: Skin-derived precursors; T: Thoracic; TH : Tyrosine hydroxylase; TIMP: tissue 
inhibitor of metalloproteinases; UCB-MSC : Umbilical cord blood mesenchymal stem cells; ≠ : 
predifferentiated. 











Table 5: Pro-angiogenic abilities of MSCs/NCSCs. 
AT-MSC: Adipose tissue mesenchymal stem cells; BMSC: Bone marrow stromal cells; FGF2: 
Fibroblast growth factor 2; h : Human; HIF: Hypoxia-inducible factor; IL : Interleukin; MΦ : 
Macrophages; MBP: Maltose binding protein; r: Rat, SC : Spinal cord; SMA: Smooth muscle actin; 
T : Thoracic; TNF: Tumor necrosis factors; VEGF: Vascular endothelial growth factor; vWF: von 
Willebrand factor. 
 
 
